Sign in
WithdrawnPhase 2

A Pharmacokinetics and Safety Study of Augmentin ES-600 in Children With CAP and ABRS

Key facts

Who runs it
GlaxoSmithKline
Where
Brazil2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Phase
Phase 2
Started
14 Oct 2023
Ended
8 Jul 2024
Type of study
Interventional
Treatments tested
  • Augmentin ES
Record updated
28 March 2025
Why it stopped
Business Decision

Who can take part

Age
3 months to 12 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 45 criteriaShow less

Who can take part

  • The participant and/or parent(s)/legal guardian(s) are willing and able to comply with the study protocol
  • In accordance with regional/local laws and regulations,
  • a. the parent(s)/legal guardian(s) has given signed informed, dated consent; and the participant has
  • b.given written assent, if applicable, to participate in the study (for participants between 7 to 12 years)
  • Age: Participant must be aged greater than or equal to (>=) 3 months to 12 years, of either gender
  • Participants who are otherwise healthy and presenting with suspected CAP
  • For participants clinically suspected of CAP, at least 3 of the following 4 criteria are applicable:
  • a) History of productive cough and/or shortness of breath
  • b)Fever greater than (>)38.5 degree Celsius (○C) (Axillary temperature)
  • c) Tachypnea as defined by Respiratory rate (RR) >= 50 breaths/minute in children up to 11 months RR >= 40 breaths/minute in children from 12 months onwards
  • d) Chest X-Ray with shadow or lobar condensation, unilateral or bilateral; For participants of ABRS:
  • The participant and/or parent(s)/legal guardian(s) are willing and able to comply with the study protocol
  • In accordance with regional/local laws and regulations,
  • a..The parent(s)/legal guardian(s) has given signed informed, dated consent; and the participant has
  • b. given written assent, if applicable, to participate in the study (for participants between 7 to 12 years)
  • Age: Participant must be between >=3 months to 12 years of either gender
  • Participants who are otherwise healthy and presenting with suspected ABRS
  • For participants of clinically suspected ABRS, the participants would be eligible if any of the following 2 of the 3 criteria stated below are met:
  • a.Children with purulent nasal discharge or daytime productive cough (which may worsen at night) or both persisting for 10 days or more without evidence of improvement
  • b. Fever > 38.3○C (Axillary temperature)
  • c. Double sickness defined as initial improvement of symptoms and further worsening/ deterioration after 5 days

Who cannot take part

  • Currently receiving or has received more than one dose of systemic antibiotic therapy within one week prior to the initiation of the study
  • History of previous hypersensitivity reaction to penicillins, cephalosporins or other Beta-lactam antibiotics
  • Received, within 48 hours of study entry, or is scheduled to receive during the study period, any medication which may alter bowel function
  • Received, within 48 hours of study entry, or is scheduled to receive during the study period, any medication which may alter renal function like probenecid
  • Participants who have chronic sinusitis (signs and symptoms lasting greater than 28 days prior to screening visit
  • Have concurrent streptococcal pharyngitis or acute otitis media (as the standard doses for both of these conditions is 10 days)
  • Any other infection or condition, which necessitates use of a concomitant systemic antimicrobial
  • Participants that are on warfarin therapy
  • Receipt of an investigational compound (non-food and drug administration [FDA] and non-Brazil National Health Surveillance Agency [ANVISA] approved) or device within the previous 30 days or five half-lives, whichever is longer, preceding the first dose of study intervention or during the study
  • A serious underlying disease as per clinician's judgment
  • Human immunodeficiency virus (HIV) infection/or any other immunosuppressive condition
  • Pre-existing liver disease(s) and/or hepatic dysfunction
  • Any pre-existing malignancy/any participants undergoing any kind of chemotherapy
  • History of amoxicillin-clavulanate associated cholestatic jaundice/hepatic dysfunction
  • History of phenylketonuria or a known hypersensitivity to aspartame
  • History of infectious mononucleosis
  • History of pseudomembranous colitis
  • Participants with symptoms suggestive of active Coronavirus disease 2019 (COVID-19) infection (that is (i.e.), fever, cough, etc.)
  • Participants with known COVID-19 positive contacts within the past 14 days
  • Pre-existing renal insufficiency (for example [e.g.], plasma creatinine > 1.5 times upper limit of normal range for age)
  • Severe ABRS/CAP requiring hospitalization
  • Evidence of leukopenia and/or thrombocytopenia
  • Significant abnormalities of the sinuses and any complications of ABRS
  • Female participants who have attained menarche

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the pharmacokinetics, safety or tolerability through treatment emergent adverse event (TEAE) and to explore primary and secondary clinical response of treatment with Augmentin ES in pediatric population presenting with CAP and ABRS in Brazil.

The group in the trial

  • Participants with CAP and ABRSTreatment being tested

    Treatment: Augmentin ES

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open Label, Single Arm Study, to Evaluate the Pharmacokinetics and Safety of Augmentin Extra Strength (ES)-600 Suspension in Children Presenting With Community Acquired Pneumonia (CAP) and Acute Bacterial Rhinosinusitis (ABRS) in Brazil
Record updated
28 March 2025